Minneapolis, MN (PRWEB) January 12, 2007
In 2005, the antibodies market was valued at an estimated US$14 billion, accounting for over 24 percent of the total protein therapeutics market. According to Arrowhead Publishers' new report Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight the value of this market is set to reach more than $16 billion in 2006. Monoclonal antibody (MAbs) therapies have been posting the fastest growth within the protein therapeutics market. This growth will continue in the coming years, boosted by a number of new MAbs on the market, new indications for successful medications, and their ability to treat conditions and diseases for which there is great unmet need.
The monoclonal class will continue to grow at a very high rate throughout the next five years, having proven their usefulness in the diagnosis of infectious diseases, the treatment of cancer and transplant rejection, as well as in the prevention of coronary artery disease.
There will, however, be increased competition as a number of "me too" drugs will gain approval during the next five years. As monoclonal antibodies are treating diseases for which there is great unmet need, new antibody therapies that have strong efficacy, good side effect profiles, and fill a niche in the treatment of diseases such as cancer and autoimmune diseases will gain success.
Alliances between pharmaceutical and biotech companies are important to the current MAb market and will continue to fuel growth on into the future. With big pharma backing smaller biotech companies in their research and clinical programs, and thus funding vital manufacturing facilities, there is little reason why the MAb market will not continue to flourish well into the 21st century.
Hundreds of monoclonal antibodies are presently undergoing various stages of clinical development. Many in the industry are utilizing ex vivo libraries (i.e. creation of a repertoire of antibodies ex vivo which can be screened for binding to a specific target) and development of transgenic mice which generate antibodies with a human protein sequence instead of a mouse protein sequence.
Finally, the limitations of existing MAb treatments -- including an increased risk of infection associated with anti-TNF-a agents (such as Humira), restrictive use to a subgroup of patients (as only some tumors over express the receptor or antigen in question), the Mab's inability to enter cells (which limits the number of treatable diseases), and the ability of tumors to shed the desired antigen into the bloodstream -- are stimulating research in the area of MAb structure and affinity, among other fields.
Arrowhead Publishers' new report: Monoclonal Antibody Therapies 2007: Competitive Landscape and Pipeline Insight is now available. For sample pages or ordering information, please contact us at 1-612-929-5203 or visit our website: http://www.arrowheadpublishers.com.
# # #